J&J Expands U.S. Footprint With Two New Manufacturing Plants Under $55 Billion Investment Plan

 

Donald Trump at Trump Force One

Johnson & Johnson Expands U.S. Footprint With Two New Manufacturing Plants Under $55 Billion Investment Plan

WASHINGTON — Johnson & Johnson announced it will build two additional manufacturing facilities in the United States, expanding its domestic production network as part of a sweeping $55 billion investment commitment aimed at strengthening American drug manufacturing.

The healthcare giant confirmed the new plants will be located in Pennsylvania and Wilson, North Carolina, marking another major step in the company’s multi-year push to bring advanced pharmaceutical production back to U.S. soil.

According to company statements, the Pennsylvania site will focus on cell therapy manufacturing, while the North Carolina facility will support drug production operations. State officials in both regions say the projects are expected to generate hundreds of new jobs, boosting local economies and positioning the U.S. as a central hub for next-generation medicine.

Johnson & Johnson said it has already invested billions of dollars over the past 10 months to expand domestic manufacturing capacity, with the long-term goal of producing “the vast majority of our advanced medicines in the United States.” A company spokesperson declined to provide exact investment figures or final site locations but confirmed planning and early development are underway.

The North Carolina expansion builds on a growing footprint in the state. Last year, J&J broke ground on a 500,000-square-foot biologics facility in Wilson. In September, the company also secured a $2 billion, 10-year manufacturing agreement with Fujifilm Biotechnologies in Holly Springs. The newly announced plant will become J&J’s third major investment in North Carolina in just over a year.

State officials said North Carolina will support the project through an Industrial Development Fund grant and a $12 million legislative appropriation to expand the training center at Wilson Community College, helping prepare a skilled workforce. The Wilson projects alone are expected to create up to 500 manufacturing jobs.

The Pennsylvania facility will further expand Johnson & Johnson’s presence in the state’s life sciences corridor, which has become a major center for biotech research, cell therapy development, and pharmaceutical manufacturing.

Johnson & Johnson’s announcement comes amid a broader industry trend as drugmakers race to secure U.S.-based supply chains. In recent months, AstraZeneca pledged $50 billion toward U.S. manufacturing and research, while AbbVie committed $100 billion over the next decade following a tariff exemption agreement with the Trump administration.

Industry analysts say these investments reflect growing pressure to reduce reliance on overseas production, strengthen national supply security, and accelerate domestic innovation.

With two more facilities now added to its roadmap, Johnson & Johnson is positioning itself at the center of what could become the largest reshoring of pharmaceutical manufacturing in decades.

---

Frequently Asked Questions (FAQs)

What did Johnson & Johnson announce?

Johnson & Johnson announced it will build two new U.S. manufacturing plants as part of its massive $55 billion domestic investment plan over the next four years.

Where will the new Johnson & Johnson plants be located?

The new facilities will be built in Pennsylvania and Wilson, North Carolina.

What will the Pennsylvania plant produce?

The Pennsylvania facility will focus on cell therapy manufacturing, supporting advanced and next-generation medical treatments.

What is the purpose of the North Carolina plant?

The Wilson, North Carolina plant will be used for drug production and pharmaceutical manufacturing, expanding Johnson & Johnson’s biologics and medicines output.

How many jobs are expected to be created?

State officials expect the projects to create hundreds of jobs, with North Carolina alone estimating up to 500 new manufacturing positions.

How much is Johnson & Johnson investing in total?

Johnson & Johnson has committed $55 billion toward U.S. manufacturing, research, and infrastructure expansion over the next four years.

Why is Johnson & Johnson expanding U.S. manufacturing?

The company says its goal is to produce the vast majority of its advanced medicines in the United States, strengthening supply chains, reducing foreign dependence, and supporting American innovation.

Is this Johnson & Johnson’s first recent U.S. investment?

No. Over the past year, J&J has already broken ground on a 500,000-square-foot biologics facility in Wilson and signed a $2 billion manufacturing deal in North Carolina.

Are other pharmaceutical companies doing the same?

Yes. Major drugmakers like AstraZeneca and AbbVie have also announced tens of billions of dollars in new U.S. investments to expand domestic production.

What support is North Carolina providing for the project?

North Carolina is offering state grants and $12 million for workforce training expansion at Wilson Community College to support the new manufacturing jobs.

---